{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:35:58Z","timestamp":1793216158063,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jacadv.2026.103047","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:23:15Z","timestamp":1787923395000},"page":"103047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Determinants and Clinical Interpretation of Circulating Transthyretin in ATTR Amyloidosis"],"prefix":"10.1016","volume":"5","author":[{"given":"Toshihiro","family":"Tsuruda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Suiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2927-7284","authenticated-orcid":false,"given":"Yunosuke","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4946-2313","authenticated-orcid":false,"given":"Soichi","family":"Komaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Moribayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinuko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2240-1510","authenticated-orcid":false,"given":"Michikazu","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kaikita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2026.103047_bib1","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103047_bib2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jacc.2022.06.026","article-title":"Screening for cardiac amyloidosis 5 to 15 years after surgery for bilateral carpal tunnel syndrome","volume":"80","author":"Westin","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103047_bib3","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/biomedicines10081906","article-title":"The journey of human transthyretin: synthesis, structure stability, and catabolism","volume":"10","author":"Sanguinetti","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jacadv.2026.103047_bib4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.clnu.2016.06.004","article-title":"Is transthyretin a good marker of nutritional status?","volume":"36","author":"Delli\u00e8re","year":"2017","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jacadv.2026.103047_bib5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1515\/CCLM.2007.051","article-title":"Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition","volume":"45","author":"Myron Johnson","year":"2007","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jacadv.2026.103047_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00011-023-01845-6","article-title":"Inflammation in heart failure: pathophysiology and therapeutic strategies","volume":"73","author":"Boulet","year":"2024","journal-title":"Inflamm Res"},{"key":"10.1016\/j.jacadv.2026.103047_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259300","article-title":"The prevalence of malnutrition and its effects on the all-cause mortality among patients with heart failure: a systematic review and meta-analysis","volume":"16","author":"Lv","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jacadv.2026.103047_bib8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamacardio.2020.5969","article-title":"Association of low plasma transthyretin concentration with risk of heart failure in the general population","volume":"6","author":"Greve","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2026.103047_bib9","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.1038\/s41467-024-50231-1","article-title":"Determinants of transthyretin levels and their association with adverse clinical outcomes among UK biobank participants","volume":"15","author":"Shetty","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacadv.2026.103047_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.05.015","article-title":"Transthyretin serum levels and clinical outcomes in patients with transthyretin amyloid cardiomyopathy","volume":"142","author":"Minervini","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jacadv.2026.103047_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","article-title":"Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin","volume":"11","author":"Hanson","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103047_bib12","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaccao.2021.08.007","article-title":"Effect of tafamidis on serum transthyretin levels in non-trial patients with transthyretin amyloid cardiomyopathy","volume":"3","author":"Falk","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.103047_bib13","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jacc.2025.03.542","article-title":"Early increase in serum transthyretin by acoramidis independently predicts improved survival in TTR amyloid cardiomyopathy","volume":"85","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103047_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103047_bib15","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103047_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeae076","article-title":"Basal inferoseptal segment is highly susceptible to deformation in the clinical spectrum of transthyretin-derived amyloid cardiomyopathy","volume":"4","author":"Tsuruda","year":"2024","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.jacadv.2026.103047_bib17","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacadv.2026.103047_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.102208","article-title":"Serum transthyretin as prognostic biomarker for cardiovascular events and mortality: a systematic review and meta-analysis","volume":"4","author":"Terentes-Printzios","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacadv.2026.103047_bib19","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103047_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/(SICI)1098-2825(1999)13:6<273::AID-JCLA4>3.0.CO;2-X","article-title":"Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort","volume":"13","author":"Ritchie","year":"1999","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.jacadv.2026.103047_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2249.1995.tb06659.x","article-title":"The acute phase protein response in patients receiving subcutaneous IL-6","volume":"102","author":"Banks","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jacadv.2026.103047_bib22","first-page":"476","article-title":"Prevalence and prognostic significance of malnutrition using 3 scoring systems among outpatients with heart failure","volume":"6","author":"Sze","year":"2018","journal-title":"JACC: Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103047_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jchf.2018.10.007","article-title":"Heart failure and liver disease: cardiohepatic interactions","volume":"7","author":"Xanthopoulos","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103047_bib24","doi-asserted-by":"crossref","first-page":"8318","DOI":"10.1038\/s41598-022-12357-4","article-title":"Potential association with malnutrition and allocation of combination medical therapies in hospitalized heart failure patients with reduced ejection fraction","volume":"12","author":"Kawakubo","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacadv.2026.103047_bib25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/13506120802525285","article-title":"Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity","volume":"15","author":"Buxbaum","year":"2008","journal-title":"Amyloid"},{"key":"10.1016\/j.jacadv.2026.103047_bib26","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.3390\/nu16152448","article-title":"Transthyretin and nutritional status in critically ill adults on parenteral nutrition: a prospective cohort study","volume":"16","author":"Linden","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.jacadv.2026.103047_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ehf2.12203","article-title":"Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis","volume":"5","author":"Takashio","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103047_bib28","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.3390\/jcm10214868","article-title":"Prognostic value of N-Terminal pro-brain natriuretic peptide and high-sensitivity troponin T levels in the natural history of transthyretin amyloid cardiomyopathy and their evolution after tafamidis treatment","volume":"10","author":"Oghina","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacadv.2026.103047_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-71446-8","article-title":"Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy","volume":"14","author":"Iino","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacadv.2026.103047_bib30","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1161\/CIRCULATIONAHA.123.067225","article-title":"Detection of circulating transthyretin amyloid aggregates in plasma: a novel biomarker for transthyretin amyloidosis","volume":"149","author":"Pedretti","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103047_bib31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaccao.2022.08.008","article-title":"Early treatment of cardiac ATTR: \u201cto Remove the Weeds, You Have to Get the Roots\u201d","volume":"4","author":"Lenihan","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.103047_bib32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/13506129.2021.2018678","article-title":"The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic transthyretin expression","volume":"29","author":"Pathak","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.jacadv.2026.103047_bib33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12883-019-1369-4","article-title":"Inflammatory profiling of patients with familial amyloid polyneuropathy","volume":"19","author":"Azevedo","year":"2019","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jacadv.2026.103047_bib34","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3945\/an.115.008508","article-title":"Plasma transthyretin as a biomarker of lean body mass and catabolic states","volume":"6","author":"Ingenbleek","year":"2015","journal-title":"Adv Nutr"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26004680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26004680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:27:06Z","timestamp":1793215626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26004680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2772963X26004680"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103047","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determinants and Clinical Interpretation of Circulating Transthyretin in ATTR Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"103047"}}